In the past week, GRNA stock has gone up by 1.39%, with a monthly decline of -38.44% and a quarterly plunge of -65.39%. The volatility ratio for the week is 8.66%, and the volatility levels for the last 30 days are 10.11% for GreenLight Biosciences Holdings The simple moving average for the past 20 days is -14.41% for GRNA’s stock, with a -85.27% simple moving average for the past 200 days.
Is It Worth Investing in GreenLight Biosciences Holdings (NASDAQ: GRNA) Right Now?
The public float for GRNA is 86.52M, and currently, short sellers hold a 3.81% ratio of that floaft. The average trading volume of GRNA on May 26, 2023 was 403.14K shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
GRNA) stock’s latest price update
GreenLight Biosciences Holdings (NASDAQ: GRNA)’s stock price has soared by 11.03 in relation to previous closing price of 0.18. Nevertheless, the company has seen a gain of 1.39% in its stock price over the last five trading days.
GRNA Trading at -43.91% from the 50-Day Moving Average
After a stumble in the market that brought GRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.65% of loss for the given period.
Volatility was left at 10.11%, however, over the last 30 days, the volatility rate increased by 8.66%, as shares sank -36.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.69% lower at present.
During the last 5 trading sessions, GRNA rose by +1.39%, which changed the moving average for the period of 200-days by -94.82% in comparison to the 20-day moving average, which settled at $0.2236. In addition, GreenLight Biosciences Holdings saw -83.36% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at GRNA starting from Builders Vision, LLC, who purchase 6,505,102 shares at the price of $3.92 back on Aug 11. After this action, Builders Vision, LLC now owns 22,348,123 shares of GreenLight Biosciences Holdings, valued at $25,500,000 using the latest closing price.
Walker Matthew Allen, the Director of GreenLight Biosciences Holdings, purchase 6,377,551 shares at $3.92 during a trade that took place back on Aug 11, which means that Walker Matthew Allen is holding 22,220,572 shares at $25,000,000 based on the most recent closing price.
Stock Fundamentals for GRNA
Equity return is now at value -374.30, with -122.80 for asset returns.
In a nutshell, GreenLight Biosciences Holdings (GRNA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.